Posts filed under: Finance

Melbourne, Australia, November 15, 2017 – Telix Pharmaceuticals Limited has today listed on the Australian Securities Exchange (ASX) after raising $50 million in a fully underwritten Initial Public Offering (IPO). The...
Continue Reading →
Melbourne, Australia, November 09, 2017 – Telix Pharmaceuticals Limited has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly supported by...
Continue Reading →
Melbourne, Australia, and LIÈGE, Belgium, Oct. 24, 2017 – Telix Pharmaceuticals (Telix) is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA...
Continue Reading →
Melbourne, Australia, October 23, 2017 – Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50 million. Click here to view the full release....
Continue Reading →
Melbourne, Australia, October 18, 2017 – Telix Pharmaceuticals Limited (Telix) is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of...
Continue Reading →
Telix Pharmaceuticals Files $50 million Underwritten Initial Public Offering. To view our prospectus, click here....
Continue Reading →
Melbourne, Australia, and San Francisco, USA, Sept. 19th, 2017 – Telix Pharmaceuticals Limited (Telix) is pleased to announce the conclusion of a collaboration and licensing agreement with CellSight Technologies, Inc....
Continue Reading →
Melbourne, Australia, Sept. 18, 2017 – Telix Pharmaceuticals Limited (Telix) is pleased to announce that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of...
Continue Reading →
Melbourne, Australia, July 31, 2017 – Telix Pharmaceuticals Limited (Telix) is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd (Cyclotek). Under the agreement,...
Continue Reading →
Melbourne, Australia and Cambridge, UK, July. 18, 2017 – Telix Pharmaceuticals Limited (Telix) is pleased to announce a licence agreement collaboration with Abzena plc (Abzena) for its prostate-specific membrane antigen...
Continue Reading →